STOCK TITAN

CytomX Therapeutics, Inc. - CTMX STOCK NEWS

Welcome to our dedicated news page for CytomX Therapeutics (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CytomX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CytomX Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
CytomX Therapeutics, Inc.

Nasdaq:CTMX

CTMX Rankings

CTMX Stock Data

110.40M
53.82M
1.19%
48.6%
4.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About CTMX

cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o